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Abstract 
 
Background  
There is a high prevalence of COVID-19 in university-age students, who are returning to campuses. There is 
little evidence regarding the feasibility of universal, asymptomatic testing to help control outbreaks in this 
population. This study aimed to pilot mass COVID-19 testing on a university research park, to assess the 
feasibility and acceptability of scaling up testing to all staff and students. 
Methods  
This was a cross-sectional feasibility study on a university research park in the East of England. All staff and 
students (5,625) were eligible to participate. All participants were offered 4 PCR swabs, which they self-
administered over two weeks. Outcome measures included: uptake; drop-out rate; positivity rates; 
participant acceptability measures; laboratory processing measures; data collection and management 
measures. 
Results 
798 (76%) of 1053 who registered provided at least one swab. 687 (86%) provided all four. 792 (99%) of 
798 who submitted at least one swab had all negative results. 6 participants had one inconclusive result. 
There were no positive results. 458 (57%) of 798 participants responded to a post-testing survey, 
demonstrating a mean acceptability score of 4.51/5, with 5 being the most positive. 
Conclusions 
Repeated self-testing for COVID-19 using PCR is feasible and acceptable to a university population.  
 
 
Full report 
Introduction 
Universities are considering methods of dealing with the transmission of COVID-19 when students return to 
campus. Student populations are likely to have a higher than average prevalence of infection (1) and in 
particular, a high rate of asymptomatic infection (2). This population is also highly mobile and more likely 
to have a large number of social contacts (3). It remains unclear how an outbreak might evolve on a 
university campus, but modelling studies suggest that students are highly interconnected, indicating 
significant potential for infectious disease transmission (4,5). Colleges in the UK and USA have already 
reported outbreaks among the student population, necessitating closure in some cases (6). The UK 
government is exploring community-wide testing for asymptomatic COVID-19 infection as a potential 
health protection tool, to enable outbreaks to be identified and controlled early (7). A SAGE consensus 
statement has suggested that such a strategy might be useful in “well-defined higher risk settings”, such as 
universities (8). This method is largely untested within a university setting, however. This pilot study was 
based in the Norwich Research Park (NRP), which includes the University of East Anglia (UEA) and a 
range of business and research institutions. The study offered four COVID-19 polymerase chain reaction 
(PCR) swabs to all staff and students on the site over a two-week period. The aim of the study was to pilot 
participant guidance materials, logistics, laboratory and data processes and the user-facing web application. 
It also aimed to establish costs and to assess participant acceptability. 
 
Methods 
All participants living or working on the NRP were eligible to participate and were invited to join the study 
via an email cascade to staff and students. Ethics approval (no. 2019/20-140) was obtained from the UEA 
research ethics committee. A secure web application was developed and hosted by the School of Computing 
Sciences at the UEA. This involved the design and implementation of software to facilitate participant sign-
up for booking slots, email authentication and data management protocols to host test results and participant 
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personal data. Participants registered on the web application and were invited to verify their email accounts 
and sign in using an industry standard authentication protocol. All those who verified their accounts were 
considered to have enrolled in the study. 180 people participated in a pre-trial, in which they returned two 
swabs. For the main study, participants were offered four swab tests over two weeks. They collected swab 
kits, self-administered the swab and returned the test in pre-booked return slots. For the purposes of this 
report the pre-trial and main trial are considered as a single trial.  
 
Swabs were processed in dedicated laboratory facilities at the Earlham Institute (EI) from Monday to Friday. 
Copan Liquid Amies Elution Swabs (Eswabs) were used for all participants. Participant samples were tested 
for the presence of SARS-COV-2 using a quantitative polymerase chain reaction (qPCR) assay. Briefly, 
nasopharyngeal swab samples were pre-treated with a lysis buffer (Cytiva) that disrupts human cells and 
viral particles to release nucleic acid into solution. Following inactivation, RNA was extracted using Sera-
Xtracta Virus/Pathogen Kit (Cytiva) on a liquid handling platform (Beckman NXp). RNA extracts were 
amplified for detection of the target genes using a set of optimised primers and probes (2019-nCoV CDC 
EUA Kit, IDT), and enzymes (qPCRBIO Probe 1-Step Go No-ROX, PCRBioystems) in a real-time PCR 
system (Quantstudio5, Thermofisher). The assay is qualitative with results assessed based on a threshold 
cycle (Ct value) to determine outcome (positive, negative, insufficient) using a combination of Ct value for 
the viral target (N1) and human internal control gene (RPP30) genes. Positive and negative controls were 
included in every RNA extraction and qPCR run for quality control. Sample data was managed at EI using 
Exemplar LIMS® from Sapio Sciences. Results data was processed from these samples using Python 3 
scripts developed at EI and running on virtual infrastructure provided by the CyVerse UK cloud. Validated 
participant results were then sent to the information systems at UEA using secure web services. 
 
Negative or inconclusive results were posted on participants’ online accounts, with additional encoding and 
encryption protocols deployed to maintain data security. A protocol for managing positive results was 
developed, including notifying participants and NHS Track and Trace by telephone, and advising 
participants to share their results with their GP. After the completion of the feasibility project, participants 
who had returned at least one swab were emailed a link to complete a short online participant feedback 
questionnaire, including questions on demographics and their experience of the project. Groups were 
compared with Chi-squared tests and free text responses were analysed by extraction of key themes. 
Participant demographics were summarised in a table, and Chi-squared tests used to compare those who 
enrolled but did not participate in the study, and those who did participate. Resource use was summarised in 
a table and the flow of participants and swabs through the study summarised in a flow diagram. 
 
Results 
Results are summarised in Figures 1 and 2 and Tables 1 and 2. 180 people participated in the pre-trial and 
another 873 in the main trial (Table 1). 458 participated in the post-study survey (Figure 2). 
19% of the eligible population enrolled in the study and 24% of these dropped out of the study prior to 
returning any samples (Figure 1). 86% (687/798) of participants who received at least one result returned all 
four swabs. 6 participants received 1 inconclusive result. All other results were negative. All participants 
received at least one negative swab. Participants could choose to return their swabs on foot or by car: 
pedestrian access sites were favoured over vehicle access sites. There was no lag between the results upload 
and participants receiving their result notification via email. The post-trial survey found that the overall 
acceptability rating was 4.5/5 stars (with 5 being the most positive) and 97% of participants would take up 
repeat testing if available. Self-swabbing received the lowest score for participant acceptability (71% agreed 
or strongly agreed that taking the swabs was easy to do). 81% of responders to the post-trial survey were 
staff and 16% were students. 
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Table 1. Participant characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Resources  
Laboratory staff time [excluding planning and reporting] 1,200 hours 
Total laboratory staff salary costs [excluding planning and reporting] £19,385 
Average sample processing time  35.5 hours 
Weekday average sample processing time 25.5 hours 
Administrative staff time estimate 500 hours 
Laboratory consumables cost estimate per test kit £3.61 
Total number of swabs supplied to participants 3,360 
Incurred costa £75,906 
Estimated in-kind contributionsb £89,612 
aThis figure represents the spend on services and equipment. The feasibility study inevitably 
incurred a high unit cost, and for example tripling the test numbers would have a negligible 
effect on cost. 
bThis figure represents the costs absorbed by the existing service.  
 
 Total   
n=1,053 a 
Percentageb 
Sex   
Female 579 55.0% 
Male 436 41.4% 
Non-binary 4 0.4% 
Prefer not to say 34 3.2% 
Age band (years)   
18-24 120 11.4% 
25-34 328 31.1% 
35-44 258 24.5% 
45-54 201 19.1% 
55-64 118 11.2% 
65+ 28 2.7% 
Ethnicity   
Asian 60 5.7% 
Black 2 0.2% 
Mixed 31 2.9% 
Other 22 2.1% 
Prefer not to say 49 4.7% 
White 889 84.4% 
aTotal participants who registered for the study and validated their account 
bThere was no significant demographic difference between those enrolled but did not 
participate and those who did participate. 
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Guidance documents 
An analysis of guidance documents provided for participants, including an instruction leaflet, standard 
emails and website text found an average Flesch reading ease score of 60.1. This indicates that material 
should be comprehensible to a person aged 13-15 years. The instruction leaflet for participants undertaking 
swabbing had a score of 74, which indicates greater readability. The text for participants opening an online 
account had a score of 46.8, which indicates that the reader requires a university education to understand the 
text. 
 
Participant acceptability 
Participant acceptability was assessed in two rounds: first by inviting email comments during the testing 
process and second by a formal survey. Key themes emerging from participant emails included eligibility 
and uncertainty about the logistical processes. There were very few emails regarding the process of self-
swabbing. 
458 participants (57%) responded to the survey, which included 11 questions about the acceptability of the 
process, with responders choosing their response to each question on a 5-point scale from ‘strongly agree’ 
(scored as 5) to ‘strongly disagree’ (scored as 1) (Figure 2). Responders were generally positive about their 
experience of the project, and the overall mean response score was 4.51 stars out of 5 (with 5 being the most 
positive). 89% of those who responded to the survey returned all four swabs. 34% of responders were 
working or studying on site, with the rest working either partly or exclusively from home. 77.5% of survey 
responders lived 5 miles or less from the NRP. Responders were not significantly more likely than all 798 
participants to have returned all 4 swabs (89% and 86% respectively, p=0.46). There were no statistically 
significant differences between those who provided all 4 swabs (n=409) and those who provided fewer than 
4 (n=49) in demographics or any answers, including the mean response score (4.54 and 4.50 stars out of 5 
respectively, p=0.83). 43 of the 49 responders who provided fewer than 4 swabs gave a reason: 21 (48%) 
were away during part of the study, and another 8 (19%) forgot or were unexpectedly busy with other 
commitments. 
266 responders (59%) answered the free text questions (“Is there any feedback you would like to share about 
any aspect of your participation in the project?” and “Is there a reason why you were unable to take any self-
swab samples?”). Responses were generally positive and included requests for ongoing testing, feedback on 
results of the study and praise for organisation and response to enquiries. Responders recommended clearer 
communication on the variability of time to receive results, as some interpreted a longer wait as being 
suggestive of a positive result. They also provided useful feedback on the usability of the web application, 
particularly the sign-up process: they requested a simpler approach, and recommended changes to the 
presentation of results to reduce anxiety. Responders also requested clearer instructions regarding packing 
samples. 
Discussion 
Main findings of this study 
827 participants took and delivered their swabs over a two-week period. The relatively low uptake can be 
explained by the timing of the study during the summer break, the absence of staff from campus due to 
working-from-home policies and a short run-up to the study. Nearly a quarter of participants dropped out of 
the study prior to returning any samples. The reasons for this were unclear from the evaluation, however 
there was no significant demographic difference between those who enrolled in the study but did not 
participate, and those who did participate. 
 
The sex distribution of the eligible population was not available, it is therefore not possible to determine 
whether the sample population (55% women) was reflective of the eligible population. The ethnic 
distribution of the study population was broadly reflective of the population of Norwich: 10.9% of 
participants were of Asian, black, mixed or ‘other’ ethnicity, compared to 9.1% for Norwich (9).  
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The study did not identify any false positives, despite this being considered a risk of universal testing (10). 
An analysis of guidance documents and participant emails indicates a need for clearer information tailored 
to the eligible population. The participant questionnaire revealed a high level of participant engagement and 
acceptability. Combined with the low drop-out rate after taking the first swab (86% of participants who 
returned at least one swab returned all four), this suggests that participants found self-swabbing and the 
collection and delivery of samples generally acceptable. 
 
The laboratory and web application processed 3046 swabs during the study. Laboratory processes were 
efficient, with an average processing time of just over 24 hours during the week. The reagent cost per test of 
£3.61 was based on a batch size of 6,000 tests which were ordered quickly from outside the UK, and we 
would expect lower costs per test in a larger initiative. The secure web application was hosted by the School 
of Computing Sciences at minimum cost. Similarly, the computing infrastructure at EI was provided in kind 
by CyVerse UK at minimal cost to the project. 
 
What is already known on this topic 
The evidence base for use of asymptomatic testing for COVID-19 as an infection control measure remains 
limited. Universal, repeat testing has been advocated however, as a means of avoiding lockdown (11). 
Universities across the world are now considering universal testing despite the pitfalls of this strategy, which 
include false positive and negative tests, the difficulty of defining an active infection and significant cost 
(10,12). UK universities and colleges in the USA have already reported outbreaks of COVID-19 (12). The 
potential for COVID-19 transmission in universities is significant, particularly shortly after the beginning of 
term when students return to campus (4,5). Models demonstrate that universal testing may have a significant 
impact on control of the virus, depending on the ability of the setting to implement other control methods 
(13). There is however, no published study assessing the feasibility or acceptability of a universal 
programme for COVID-19 testing on a university campus.  
 
What this study adds 
This pilot study indicates that universal testing on a university campus is both feasible and acceptable to the 
population. A strength of this study is that it trialled the feasibility of repeat testing for COVID-19 in a 
relatively large, asymptomatic population within a research park and university campus. Participants 
included both staff and students and the findings can be applied both to a larger study on the same site and to 
other university contexts. There was a high level of participant engagement with the study. This study has 
demonstrated that clear, consistent communications and an intuitive web application are necessary for 
helping participants to understand the need for testing and the process of undertaking and returning the test. 
 
Both universal testing and the current UK national public health strategy of testing symptomatic people via a 
local testing site have strengths and weaknesses. The current national strategy of symptomatic testing is 
adequate when there are few cases in the community, and is cheaper in the short term, but risks allowing 
undetected spread of COVID-19 when cases start to rise in a community, particularly when results take 
more than 24 hours to be reported. The main potential problem with universal testing is that it may generate 
false positives, and therefore unnecessary contact tracing and isolation. It is also more expensive in the short 
term. There were no false positives out of 3,046 tests in this study. The main advantage of universal testing 
is that it can identify infectious asymptomatic cases and isolate them before they can infect others in the 
community. This is a major benefit on a campus university with large numbers of students in a community 
where isolation and social spacing may be challenging to maintain, and where a major outbreak would have 
serious consequences for students’ education, the university, and the local community.  
 
Limitations of this study 
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Limitations of the study include the relatively low uptake and the low prevalence of COVID-19 in this 
population, which meant that processes for managing positive results could not be tested. At the time of the 
study, community prevalence of COVID-19 was approximately 1 in 1700 people(15). As this was a self-
selecting cohort of university staff and students, motivation to participate may be higher than in the general 
population. The findings are generalisable to university staff but may be less generalisable to new 
undergraduates. This study used PCR swabs but acceptability of some alternative testing methods, such as 
saliva testing, may be even higher. 
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Figure 1. Flow of participants through the study and main results 
 
 
 
 
 
 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted October 1, 2020. .https://doi.org/10.1101/2020.09.22.20199455doi: medRxiv preprint 
 
Figure 2. Participant responses 
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